Výsledky vyhledávání - "Nathaniel Brittain"

Akademický článek

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.

Autor: Tandakha N. Dieye, Birahim P. NDiaye, Alle B. Dieng, Marema Fall, Nathaniel Brittain, Samantha Vermaak, Makhtar Camara, Halimatou Diop-Ndiaye, Ndeye Fatou Ngom-Gueye, Papa A. Diaw, Coumba Toure-Kane, Papa S. Sow, Souleymane Mboup, Helen McShane

Publikováno v: PLoS ONE, Vol 8, Iss 10 (2013)

Externí odkaz: https://doaj.org/article/64337f98b6c2427d8dc4cb4802ed6d11

Zobrazit plný text záznamu

Akademický článek

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Autor: Tandakha N Dieye, Birahim P Ndiaye, Alle B Dieng, Marema Fall, Nathaniel Brittain, Samantha Vermaak, Makhtar Camara, Halimatou Diop-Ndiaye, Ndeye Fatou Ngom-Gueye, Papa A Diaw, Coumba Toure-Kane, Papa S Sow, Souleymane Mboup, Helen McShane

Publikováno v: PLoS ONE, Vol 8, Iss 6, p e67177 (2013)

Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic. Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal. 24 patients were enrolled: Group 1∶12, antiretroviral therap

Externí odkaz: https://doaj.org/article/a96c1cb6694d4d57b5e5bcf005ef770e

Zobrazit plný text záznamu

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

Autor: Nazma Mansoor, Hassan Mahomed, Sizulu Moyo, Adrian V. S. Hill, Willem A. Hanekom, Mark Hatherill, Ashley Veldsman, Sebastian Gelderbloem, Thomas J. Scriba, Alison M. Lawrie, Helen McShane, Linda van der Merwe, Nathaniel Brittain, Alana Keyser, Erica Smit, Michele Tameris, Gregory D. Hussey, Anthony Hawkridge, Fatima Isaacs

Modified vaccinia Ankara-expressing Ag85A (MVA85A) is a new tuberculosis (TB) vaccine aimed at enhancing immunity induced by BCG. We investigated the safety and immunogenicity of MVA85A in healthy adolescents and children from a TB endemic region, wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565c078aba324398d9823dd7f136b1e3
https://doi.org/10.1002/eji.200939754

Zobrazit plný text záznamu

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults

RATIONALE: Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. OBJECTIVE: To determine the safety and immunogenicity of MVA85A, a novel TB v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af96df0967024ce640bd0769fad43105
https://ora.ox.ac.uk/objects/uuid:56faaaa7-18af-4ab2-9293-960f3aba3c73

Zobrazit plný text záznamu

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants

Autor: Sarah Rowland-Jones, Helen McShane, Martin O. C. Ota, Nicola Williams, Patrick K. Owiafe, Nathaniel Brittain, Simon Donkor, Aderonke Odutola, Olumuyiwa Owolabi, Richard A. Adegbola, Adrian V. S. Hill

New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vacc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff7f2b94fd3e6ea704547f745b31a013
https://doi.org/10.1126/scitranslmed.3002461

Zobrazit plný text záznamu

Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants

Publikováno v: The Journal of Infectious Diseases. 203:1832-1843

(See the editorial commentary by Dockrell, on pages 1708-9.)Background. BCG, the only licensed tuberculosis vaccine, affords poor protection against lung tuberculosis in infants and children. A new tuberculosis vaccine, which may enhance the BCG-indu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85daa0c499db89b7fc2147073a7c1d0c
https://doi.org/10.1093/infdis/jir195

Zobrazit plný text záznamu

Correction: Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

Autor: Thomas J. Scriba, Michele Tameris, Nazma Mansoor, Erica Smit, Linda van der Merwe, Fatima Isaacs, Alana Keyser, Sizulu Moyo, Nathaniel Brittain, Alison Lawrie, Sebastian Gelderbloem, Ashley Veldsman, Mark Hatherill, Anthony Hawkridge, Adrian V. S. Hill, Gregory D. Hussey, Hassan Mahomed, Helen McShane, Willem A. Hanekom

Publikováno v: European Journal of Immunology. 41:1501-1501

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b3eddd2384287da4c3ed5239dfdbf64
https://doi.org/10.1002/eji.201190030

Zobrazit plný text záznamu

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity

Autor: Nicola Williams, David W. Porter, Alison M. Lawrie, Helen McShane, Clare R. Sander, Angela M. Minassian, Ian D. Poulton, Rosalind Rowland, Ansar A. Pathan, Iman Satti, Nathaniel Brittain

Publikováno v: Trials in Vaccinology. :27-35

© 2012 Elsevier Ltd. All rights reserved Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a candidate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341d3c4fc7215a8198ef2bbefe56f5b4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání